Ergothioneine (ERG) is a histidine-derived thiol compound suggested to function as an antioxidant and cytoprotectant in humans. Therefore, experimental trials have been conducted applying ERG from mushrooms in dietary supplements and as a cosmetic additive. However, this method of producing ERG is expensive; therefore, alternative methods for ERG supply are required. Five Mycobacterium smegmatis genes, egtABCDE, have been confirmed to be responsible for ERG biosynthesis. This enabled us to develop practical fermentative ERG production by microorganisms. In this study, we carried out heterologous and high-level production of ERG in Escherichia coli using the egt genes from M. smegmatis. By high production of each of the Egt enzymes and elimination of bottlenecks in the substrate supply, we succeeded in constructing a production system that yielded 24 mg/L (104 μM) secreted ERG.
■ INTRODUCTION
Ergothioneine (ERG), a histidine-derived thiol compound, was isolated from an ergot fungus, Claviceps purpurea, more than a century ago. ERG is also known to be synthesized in actinobacteria, cyanobacteria, and a fission yeast. 1−3 Recent studies show that ERG functions as an antioxidant, such as glutathione, mycothiol, and bacillithiol. There is no direct evidence for biosynthesis of ERG in humans. However, ERG has been reported to be accumulated in various cells and tissues at high concentrations, probably by intake from diets, such as mushrooms and red beans, that contain relatively large amounts of ERG through an ERG-specific organic cation transporter, OCTN1. 4, 5 The presence of the ERG-specific transporter and the extensive accumulation of ERG in tissues suggest that ERG should have significant biological functions in humans. Although the true physiological role of ERG in humans has yet to be fully understood, ERG has been shown by in vitro experiments to function as an antioxidant and a cytoprotectant. Therefore, applications of ERG in dietary supplements and as a cosmetic additive have been explored, and there is an increasing demand for ERG. 6 Mushrooms have traditionally been the source of ERG. 7 However, slow growth, low content, and timeconsuming purification procedures lead to a high manufacturing cost. Therefore, alternative and sustainable sources of ERG are necessary.
One such reliable and practical method is a fermentative process using microorganisms, such as actinobacteria and cyanobacteria, that are known to produce ERG. However, their ERG productivities are very low (1.18 mg/g of dry weight after 4 weeks of cultivation of Mycobacterium avium and 0.8 mg/g of dry weight of Oscillatoria sp.), 2, 8 and thus, genetic and metabolic engineering are indispensable for industrial production. Until recently, however, there were no reports on ERG biosynthesis genes and enzymes. In 2010, five genes in Mycobacterium smegmatis, egtABCDE, were confirmed to be responsible for ERG biosynthesis (Figure 1 ). 9 In the biosynthetic pathway, EgtD catalyzes the formation of hercynine (HER) by transfer of three methyl groups derived from S-adenosylmethionine (SAM) to L-histidine (L-His). Then, EgtB catalyzes O 2 -dependent C−S bond formation between γ-glutamylcysteine (γGC) supplied by EgtA and HER to form hercynyl-γ-glutamylcysteine sulfoxide (γGC-HER). This is followed by removal of the L-glutamate (L-Glu) moiety by EgtC, an amidohydrolase, to produce hercynylcysteine sulfoxide (Cys-HER). Then, EgtE, a PLP-dependent C−S lyase, catalyzes the formation of ERG with concomitant formation of pyruvate and ammonia as side products.
In this study, we developed heterologous and high-level production of ERG in Escherichia coli using the egt genes from M. smegmatis. By high production of each of the Egt enzymes and elimination of bottlenecks in substrate supply, the production system yielded 24 mg/L (104 μM) secreted ERG.
were of analytical grade and purchased from Wako Pure Chemical Industry or Sigma-Aldrich Japan. Primers were obtained from FASMAC Co., Ltd. (Kanagawa, Japan). Enzymes and kits for DNA manipulation were purchased from Takara Bio, Inc. (Shiga, Japan) or New England BioLabs Japan, Inc. (Tokyo, Japan). Polymerase chain reaction (PCR) was carried out using a GeneAmp PCR System 9700 thermal cycler (Thermo Fisher Scientific, Inc., Waltham, MA, U.S.A.) with Tks Gflex DNA polymerase (Takara Bio). General genetic manipulations of E. coli were performed according to standard protocols. High-resolution electrospray ionization Fourier transform mass spectrometry (HR-ESI−FT−MS) analysis was performed using an Exactive system (Thermo Fisher Scientific, Inc.).
Bacterial Strains and Cultures. Microorganisms used in this study are summarized in Table 1 . E. coli XL1-Blue (Nippon Gene Co., Ltd., Tokyo, Japan), BL21(DE3) (Merck KGaA, Darmstadt, Germany), and BW25113 (National Institute of Genetics, Shizuoka, Japan), which is a high producer of L-cysteine (L-Cys) used for a sulfur donor of ERG, 10 were used for plasmid construction, protein production, and ERG production, respectively. The media used were LB and M9Y minimal medium prepared by adding 1% (w/v) glucose, 5 mM MgSO 4 , 0.1 mM CaCl 2 , and 0.1% (w/v) yeast extract (Becton, Dickinson and Company, Franklin Lakes, NJ, U.S.A.) to M9 minimal salts (Becton, Dickinson and Company). Ampicillin (Ap), chloramphenicol (Cm), kanamycin (Km), streptomycin (Sm), and tetracycline (Tc) were added to the media at concentrations of 100, 33, 25, 20, and 5 mg/L, if necessary. Optical density (OD) at 600 nm was measured with a NanoDrop 2000C spectrophotometer (Thermo Fisher Scientific, Inc.).
Preparation of Egt Recombinant Enzymes. Detailed plasmid construction methods are described in Supplementary Methods 1 of the Supporting Information, and the plasmids are summarized in Table 2 . Briefly, EgtB, EgtC, EgtD, and EgtE were amplified by PCR using M. smegmatis genomic DNA as the template and appropriate primers (Table S1 of the Supporting Information), in which restriction sites were introduced at the N and C termini. The PCR products were respectively cloned into the expression vectors. The plasmids obtained were introduced into E. coli BL21(DE3). A liquid culture of the transformant in LB supplied with appropriate antibiotics was induced by adding 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) when the optical density at 600 nm reached about 0.6. The cultivation was continued for an additional 16 h at 20°C. The production of each recombinant enzyme was analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS−PAGE) with Coomassie Brilliant Blue staining. The purification of each recombinant protein was carried out using nickel−nitrilotriacetic acid (Ni−NTA) agarose 
■ RESULTS AND DISCUSSION
The most reliable strategy for high production of ERG is overproduction of each of the enzymes for ERG biosynthesis and then optimization of any inefficient biosynthetic step(s) (identified by intermediate accumulation) by molecular genetics and metabolic engineering. If no intermediates accumulate, supply of the initial substrates, L-His, L-Glu, L-Cys, and L-Met, should be enhanced.
ERG biosynthetic genes are present in some microorganisms, such as actinobacteria, cyanobacteria, and α-proteobacteria. 11 Among these bacteria, we selected M. smegmatis as the gene source, because the ERG biosynthetic pathway was first identified in this strain and the biosynthesis genes constitute an operon. 9 Because egtB, egtC, and egtE are translationally coupled, we first tried expressing the egt genes as the operon with tac and T7 promoters. We constructed several plasmids using pQE1a-Red and pET-21a, but ERG productivities of transformants harboring the plasmids were low (less than 0.2 mg/L). Therefore, we overexpressed egt genes stepwise under the control of individual promoters by checking production of recombinant enzymes and their activities by production of intermediate compounds (HER, γGC-HER, and Cys-HER) and ERG by in vitro experiment (Figure 1) . Because E. coli has an egtA orthologue, gshA, which is responsible for glutathione biosynthesis, 12 we expressed the other genes, egtB, egtC, egtD, and egtE. We also prepared the intermediate compounds, which are not commercially available, with the recombinant enzymes to obtain standards for quantitative analysis (Supplementary Methods 2 of the Supporting Information).
Overproduction of Recombinant Enzymes. For overproduction of Egt enzymes, we used pQE1a-Red and pCF1s-Red, both of which are home-constructed and compatible vectors with the tac promoter for protein production ( Figure S1 of the Supporting Information). As Figure S2 of the Supporting Information shows, transformants harboring pCF1s-MsD carrying egtD overproduced EgtD in soluble form. To confirm whether the recombinant protein had the expected activity, we carried out in vitro experiments with cell-free extracts containing the recombinant enzyme. 9, 13 The cell-free extracts were incubated with L-His and excess SAM. After the reaction, the product was analyzed by LC−ESI−MS. A specific peak with the same retention time and mass spectrometry (MS) spectrum as the HER standard was clearly detected after 1 h of incubation, demonstrating that EgtD converted L-His into HER ( Figure S3 of the Supporting Information).
We next overproduced recombinant EgtB using pQE1a-Red ( Figure S1 of the Supporting Information) and changed the probable start codon TTG into ATG. However, recombinant EgtB formed inclusion bodies in multiple culture conditions. Therefore, a plasmid from which a recombinant enzyme is produced as a maltose binding protein (MBP)-fused enzyme was examined. We successfully produced a MBP-fused EgtB in a soluble form in transformants harboring pQE1a-mMsB. To confirm whether the recombinant enzyme had the expected activity, we carried out in vitro experiments with purified recombinant enzyme ( Figure S4 of the Supporting Information). 9 The recombinant MBP-fused EgtB was incubated with HER and γGC for 2 h. As Figure S5 Finally, overproduction of recombinant EgtC and EgtE was examined. We first used the same vector as for EgtB production, but no production of either enzyme was observed. We then examined a plasmid from which a recombinant enzyme is produced as a His-tagged enzyme. In this case, both EgtC and EgtE were successfully overproduced. To confirm whether the recombinant enzymes had the expected activity, we carried out in vitro experiments with the purified recombinant enzymes ( Figure S4 of the Supporting Information). 9 Recombinant EgtC was incubated with enzymatically prepared γGC-HER. After 17 h of reaction, the product was analyzed by LC−ESI−MS. As shown in Figure 3 Simultaneous Production of Egt Enzymes for ERG Production. To reconstruct the ERG-producing pathway in E. coli, we optimized the production conditions in a stepwise manner: HER, then γGC-HER, and finally ERG production (Figures 1 and 2) .
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The first step was HER production. E. coli BW25113 harboring pCF1s-MsD (named strain ET1) was cultured in M9Y medium, and 91 ± 2 mg/L HER (460 ± 10 μM) was produced in the culture broth after 48 h. We then carried out feeding experiments with L-His and L-Met, because amino acid biosynthesis in E. coli is strictly regulated by feedback inhibition and/or transcriptional repression. L-Met and L-His feeding increased the yield: 164 ± 3 mg/L HER (833 ± 15 μM) was produced after 48 h of cultivation ( Figure 5 ). After this, L-His and L-Met feeding was employed in all in vivo production experiments.
We next carried out in vivo co-production of EgtD and EgtB for γGC-HER production. Transformants of E. coli BW25113 carrying both pCF1s-MsD and pQE1a-mMsB (strain ET2) were cultivated in the medium supplemented with L-His and L-Met. As Figure 6 shows, we confirmed 24 ± 1 mg/L γGC-HER (52 ± 2 μM) production after 24 h of cultivation, indicating that EgtB converted HER to γGC-HER using endogenous γGC in E. coli. However, accumulation of 3-fold higher amounts of HER (110 ± 5 mg/L) than Cys-HER (36 ± 2 mg/L) was 
Article detected, suggesting that γGC-HER production was ratelimiting.
For simultaneous expression of all egt genes, egtC and egtE, both of which were expressed from the tac promoter of pQE1a, were recloned into plasmid pACYCDuet-1, which is compatible with pQE1a-Red and pCF1s-Red, to construct pAC1c-hMsC/ hMsE (Figure 2 and Supplementary Methods 2 of the Supporting Information). The plasmid was successfully constructed, and production of both enzymes in soluble forms in E. coli was confirmed by SDS−PAGE ( Figure S6 of the Supporting Information). The plasmid was introduced into strain ET2 to construct strain ET3, and recombinant enzyme production was examined. As Figure S7 of the Supporting Information shows, all of the enzymes were produced in soluble forms. We then examined ERG production. Strain ET3 produced 19 ± 2 mg/L (83 ± 8 μM) ERG together with 73 ± 15 mg/L (370 ± 76 μM) HER in the culture broth after 72 h of cultivation ( Figure 7 and Table 3 ). These results suggested that the EgtB-catalyzed reaction is a bottleneck.
ERG Production and Improvement of Rate-Limiting Steps. Considering that EgtB was overproduced in a soluble form in the producing strain ET3 and that it showed enough activity in in vitro experiments, we considered that insufficient supply of γGC, the substrate of EgtB, might cause the accumulation of HER. To test this hypothesis, overproduction of γGC synthetase was carried out. To produce γGC synthetase, the gshA gene from E. coli 12 was cloned and inserted into pQE1a-mMsB to construct pQE1a-mMsB/EcA. Although MBP-fused EgtB and GshA were produced in soluble forms in E. coli BW25113 harboring the three plasmids (strain ET4) ( Figure S8 of the Supporting Information), ERG productivity was decreased in comparison to that of strain ET3 to 17 ± 1 mg/L (72 ± 2 μM) after 72 h of cultivation (Table 3 ). In comparison of SDS−PAGE data for strains ET3 and ET4 (Figures S7 and S8 of the Supporting Information), soluble MBP-fused EgtB was found to be decreased in strain ET4. This could be the reason for the reduced productivity.
We then employed another strategy to enhance the γGC supply. In ERG biosynthesis, γGC is used as a sulfur donor. In particular, L-Cys is a net sulfur donor, because the L-Glu moiety of γGC is released by EgtC. Therefore, reinforcement of L-Cys flux may be effective in enhancing γGC flux and ERG production. Because L-Cys addition into media was reported to be toxic to E. coli cells, 14 we employed another strategy. We have been studying a L-Cys biosynthetic pathway in E. coli and demonstrated that thiosulfate (S 2 O 3 2− ) was a better sulfur source than sulfate (SO 4 2− ) for high L-Cys production. 10 We therefore fed thiosulfate into the growth media. When strain ET3 was cultured in M9Y supplemented with L-Met, L-His, and thiosulfate, ERG productivity was increased to 24 ± 4 mg/L (104 ± 17 μM) ( Table 3) , indicating that reinforcement of L-Cys flux was very effective in enhancing the ERG production.
In conclusion, to establish a reliable and practical method for ERG supply, fermentative ERG production by microorganisms was investigated. We heterologously overexpressed genes egtBCDE of M. smegmatis in E. coli and succeeded in the production of ERG (19 mg/L). Reinforcement of the γGC supply by feeding of thiosulfate, a suitable sulfur donor for high L-Cys production, resulted in higher ERG production (24 mg/ L). Considering that the reported ERG contents of mushrooms were from 0.15 to 7.27 mg/g of dry weight, 7 our system might become an alternative method for ERG supply. However, significant amounts of HER still accumulated, suggesting that more supply of γGC and L-Cys by metabolic engineering and use of another EgtB with higher activity are indispensable for high-level production of ERG. 
